Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Criteria the registry did not label

• Inclusion (key)
• Confirmed generalized MG: Diagnosis ≥6 months before screening, anti-AChR antibody positive, and supportive diagnostic evidence (e.g., abnormal SFEMG/RNS or response to anticholinesterase therapy).
• Disease severity: MGFA Class II-IV at screening.
• Symptoms threshold: MG-ADL ≥6 at screening and on Day 1.
• Meningococcal vaccination: Up to date within 3 years or vaccinated before first dose to mitigate risk with complement inhibition.
• Body weight: ≥40 kg.
• Vaccinated against meningococcal infections within the 3 years prior to, or at the time of, initiating study drug.
  • Exclusion (key)
• Thymic disease:
  • Untreated thymic malignancy/carcinoma/thymoma excluded.
  • Prior thymic malignancy allowed only if treatment completed \>5 years, no recurrence in last 5 years, and clear CT/MRI within 6 months.
  • Prior benign thymoma allowed if confirmed benign, treatment \>12 months ago, no recurrence in last 12 months, and clear CT/MRI within 6 months; otherwise follow malignancy rules.
  • Thymectomy within the last 12 months
• Infection risk:
  • History of meningococcal disease or unresolved infection, or active systemic infection within 14 days of Day 1 excluded.
  • Persistent/recurrent infections in past 12 months that add risk
  • HIV, active HBV (HBsAg+ or anti-HBc+ with anti-HBs-), or active HCV (unless documented successful treatment/SVR)
• Safety/medical status:
  • Hypersensitivity to study drug components (including murine proteins)
  • Recent hospitalization ≥24 hours within 28 days of screening
  • Substance use disorder per DSM within 12 months.
  • Recent/other malignancy within 5 years (except as above for thymic).
• Prior/Concomitant Therapy
  • Complement inhibitor within \< 5 half-lives before Day 1.
  • Human neonatal Fc receptor (FcRn) inhibitor within \< 5 half-lives before Day 1.
  • Rituximab, ocrelizumab or other B cell-depleting therapy within ≤ 6 months (180 days) before Day 1.
  • Periodic (chronic) administration of PP/PE, or IVIg as maintenance therapy received or scheduled within ≤ 6 months before Day 1
• Key labs:
  • ALT \>2× ULN, direct bilirubin \>2× ULN.
  • eGFR \<30 mL/min/1.73 m² or on dialysis.
  • Any other clinically significant lab abnormality making participation unsafe.
  • Note: Other protocol-defined criteria may apply and should be verified during full eligibility review.